Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position

Key Points

• Birch Hill Investment Advisors reduced its Edwards Lifesciences stake by 1.7% in the third quarter, selling 12,355 shares and retaining 723,022 shares valued at approximately $62.4 million.
• Institutional investors own 79.46% of Edwards Lifesciences, while several other funds initiated positions. The stock recently opened at $86.52, with a 52-week range of $72.67 to $96.29.
• Edwards exceeded quarterly expectations with $0.78 EPS and $1.74 billion in revenue, up 13.6% year over year. Analysts maintain a Moderate Buy consensus with an average price target of $100.27.

Birch Hill Investment Advisors LLC lowered its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 723,022 shares of the medical research company's stock after selling 12,355 shares during the quarter. Edwards Lifesciences comprises about 2.7% of Birch Hill Investment Advisors LLC's portfolio, making the stock its 14th biggest holding. Birch Hill Investment Advisors LLC owned about 0.13% of Edwards Lifesciences worth $62,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the 1st quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Pin Oak Investment Advisors Inc. purchased a new position in Edwards Lifesciences in the second quarter worth approximately $26,000. Finally, GK Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $26,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

EW stock opened at $86.52 on Friday. The stock's fifty day simple moving average is $88.44 and its 200-day simple moving average is $86.33. Edwards Lifesciences Corporation has a 52-week low of $72.67 and a 52-week high of $96.29. The stock has a market capitalization of $49.82 billion, a price-to-earnings ratio of 49.72, a price-to-earnings-growth ratio of 2.27 and a beta of 0.87. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences's revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.00 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Barclays upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Wednesday, October 7th. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Citigroup reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Monday, October 5th. Truist Financial upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a research report on Thursday, July 16th. Finally, Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Insiders Place Their Bets

In other news, VP Annette Brüls sold 2,644 shares of the company's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,045 shares of company stock worth $451,596 in the last 90 days. 0.31% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.